SCHEMBL12390209

SCHEMBL12390209

CN1CCN(C(=O)C2C3CCC(O3)C2C(=O)S)CC1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TFPI2 P48307 7/20 0.74
▸ PPP5C P53041 2/20 0.74
▸ PPP2CA P67775 1/20 0.74
▸ NPY4R P50391 1/20 0.74
▸ HTT P42858 1/20 0.42
▸ LMNA P02545 2/20 0.41
▸ TSHR P16473 2/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GMNN O75496 1/20 0.37
▸ PMP22 Q01453 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ THPO P40225 1/20 0.37
▸ CTSB P07858 1/20 0.37
▸ CTSS P25774 1/20 0.37
▸ CTSK P43235 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9880161 1.00 TFPI2 (0.74) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL19512780 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL2832350 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL19501013 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL12390164 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL26377801 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL9880148 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
Lb-100 SCHEMBL13311584 0.85 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RHTT
SCHEMBL1572846 0.84 TFPI2 (0.74) TFPI2PPP5CPPP2CANPY4RHTT
SCHEMBL12122108 0.83 TFPI2 (0.65) TFPI2PPP5CPPP2CANPY4RLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 — — US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 — — US disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 — — EP disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 — — US disclosed
US-9079917-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2015-07-14 — — US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 — — US disclosed
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. 2015-02-12 — — US disclosed
US-8822461-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2014-09-02 — — US disclosed
US-8822461-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2014-09-02 — — US disclosed
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2013-11-14 — — US disclosed
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2013-11-14 — — US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 — — US disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 — — US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 — — US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 — — US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 — — US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 — — US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 — — US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20150045373-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20130302402-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L TFPI2 4843/4885PPP5C 2860/4885PPP2CA 2048/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback